Brain-Targeted Drug Delivery
Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presen...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | ONIX_20221025_9783036552828_48 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869519099500953600 |
|---|---|
| collection | Directory of Open Access Books |
| description | Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems. |
| format | Online |
| id | doab-20.500.12854ir-93194 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-931942024-04-09T23:16:34Z Brain-Targeted Drug Delivery Sousa, Flávia drug delivery into the brain transendothelium based on receptor-mediated transcytosis immunotherapy Alzheimer’s disease anti-tau and anti-receptor bispecific monoclonal antibodies Alzheimer’s disease-relevant tau species temporal-spatial pathological Aβ and tau distribution interactions between Aβ and tau tau clearance in microglia tau clearance in neurons liposome nanoparticle seizure laser ultrasound naringenin nanostructured lipid carrier intranasal delivery central composite rotatable design depression pomegranate seed oil nasal delivery system memory impairment movement impairment delivery to brain improved memory phospholipid oily gel high-grade glioma diffuse midline glioma glioblastoma IL-13Rα2 IL-13 immunotoxin targeted therapy GB-13 IL13.E13K-PE4E receptor expression acetaminophen blood–brain barrier claudin-5 CNS drug delivery opioids tight junction microdialysis cerebral open flow microperfusion electrochemical biosensors macromolecules tolcapone microparticles nanoparticles PLGA Parkinson’s disease nose to brain delivery gene therapy polyplexes hyaluronidase glycol chitosan brain cancer chemoattractant CXCL CXCR glioblastoma multiforme 3D cell culture systems non-human primate convection-enhanced delivery neurosurgery optogenetics blood-brain barrier brain targeted therapy drug delivery cerebrospinal fluid microcirculation brain biodistribution n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems. 2022-10-25T09:01:38Z 2022-10-25T09:01:38Z 2022 book ONIX_20221025_9783036552828_48 9783036552828 9783036552811 https://directory.doabooks.org/handle/20.500.12854/93194 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/6091 https://mdpi.com/books/pdfview/book/6091 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-5281-1 10.3390/books978-3-0365-5281-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036552828 9783036552811 260 open access |
| spellingShingle | drug delivery into the brain transendothelium based on receptor-mediated transcytosis immunotherapy Alzheimer’s disease anti-tau and anti-receptor bispecific monoclonal antibodies Alzheimer’s disease-relevant tau species temporal-spatial pathological Aβ and tau distribution interactions between Aβ and tau tau clearance in microglia tau clearance in neurons liposome nanoparticle seizure laser ultrasound naringenin nanostructured lipid carrier intranasal delivery central composite rotatable design depression pomegranate seed oil nasal delivery system memory impairment movement impairment delivery to brain improved memory phospholipid oily gel high-grade glioma diffuse midline glioma glioblastoma IL-13Rα2 IL-13 immunotoxin targeted therapy GB-13 IL13.E13K-PE4E receptor expression acetaminophen blood–brain barrier claudin-5 CNS drug delivery opioids tight junction microdialysis cerebral open flow microperfusion electrochemical biosensors macromolecules tolcapone microparticles nanoparticles PLGA Parkinson’s disease nose to brain delivery gene therapy polyplexes hyaluronidase glycol chitosan brain cancer chemoattractant CXCL CXCR glioblastoma multiforme 3D cell culture systems non-human primate convection-enhanced delivery neurosurgery optogenetics blood-brain barrier brain targeted therapy drug delivery cerebrospinal fluid microcirculation brain biodistribution n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues Brain-Targeted Drug Delivery |
| title | Brain-Targeted Drug Delivery |
| title_full | Brain-Targeted Drug Delivery |
| title_fullStr | Brain-Targeted Drug Delivery |
| title_full_unstemmed | Brain-Targeted Drug Delivery |
| title_short | Brain-Targeted Drug Delivery |
| title_sort | brain targeted drug delivery |
| topic | drug delivery into the brain transendothelium based on receptor-mediated transcytosis immunotherapy Alzheimer’s disease anti-tau and anti-receptor bispecific monoclonal antibodies Alzheimer’s disease-relevant tau species temporal-spatial pathological Aβ and tau distribution interactions between Aβ and tau tau clearance in microglia tau clearance in neurons liposome nanoparticle seizure laser ultrasound naringenin nanostructured lipid carrier intranasal delivery central composite rotatable design depression pomegranate seed oil nasal delivery system memory impairment movement impairment delivery to brain improved memory phospholipid oily gel high-grade glioma diffuse midline glioma glioblastoma IL-13Rα2 IL-13 immunotoxin targeted therapy GB-13 IL13.E13K-PE4E receptor expression acetaminophen blood–brain barrier claudin-5 CNS drug delivery opioids tight junction microdialysis cerebral open flow microperfusion electrochemical biosensors macromolecules tolcapone microparticles nanoparticles PLGA Parkinson’s disease nose to brain delivery gene therapy polyplexes hyaluronidase glycol chitosan brain cancer chemoattractant CXCL CXCR glioblastoma multiforme 3D cell culture systems non-human primate convection-enhanced delivery neurosurgery optogenetics blood-brain barrier brain targeted therapy drug delivery cerebrospinal fluid microcirculation brain biodistribution n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues |
| topic_facet | drug delivery into the brain transendothelium based on receptor-mediated transcytosis immunotherapy Alzheimer’s disease anti-tau and anti-receptor bispecific monoclonal antibodies Alzheimer’s disease-relevant tau species temporal-spatial pathological Aβ and tau distribution interactions between Aβ and tau tau clearance in microglia tau clearance in neurons liposome nanoparticle seizure laser ultrasound naringenin nanostructured lipid carrier intranasal delivery central composite rotatable design depression pomegranate seed oil nasal delivery system memory impairment movement impairment delivery to brain improved memory phospholipid oily gel high-grade glioma diffuse midline glioma glioblastoma IL-13Rα2 IL-13 immunotoxin targeted therapy GB-13 IL13.E13K-PE4E receptor expression acetaminophen blood–brain barrier claudin-5 CNS drug delivery opioids tight junction microdialysis cerebral open flow microperfusion electrochemical biosensors macromolecules tolcapone microparticles nanoparticles PLGA Parkinson’s disease nose to brain delivery gene therapy polyplexes hyaluronidase glycol chitosan brain cancer chemoattractant CXCL CXCR glioblastoma multiforme 3D cell culture systems non-human primate convection-enhanced delivery neurosurgery optogenetics blood-brain barrier brain targeted therapy drug delivery cerebrospinal fluid microcirculation brain biodistribution n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues |
| url | ONIX_20221025_9783036552828_48 |